Pharmacorp Rx Inc. · TSXV:PCRX
Pharmacorp Rx — Investor Presentation (October 2026)
26 slides from Pharmacorp Rx's investor presentation, Oct 1, 2026
Slide 1: Investor Presentation Fall 2026
(TSXV: PCRX) Investor Presentation Fall 2026
Slide 2: Disclaimers: Forward-Looking Information and Non-IFRS Financial Measures
Disclaimers: Forward-Looking Information, Prospective Investor Disclaimer, Industry and Market Data and Non-IFRS Financial Measures Forward-Looking Information: This presentation contains “forward-looking information” regarding PharmaCorp Rx Inc. (“PharmaCorp”) within the meaning of applicable Canad
Slide 3: Disclaimers: Prospective Investor, Industry and Market Data
Disclaimers: Forward-Looking Information, Prospective Investor Disclaimer, Industry and Market Data and Non-IFRS Financial Measures Prospective Investor Disclaimer: This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction. Any o
Slide 4: Buy Integrate Operate
Buy Integrate Operate PHARMACIES ACROSS CANADA
Slide 5: ROFR Without Capital
PHARMACHOICE CANADA’S STRUCTURAL CHALLENGE (PRE-PHARMACORP) 1,161+ Independent Pharmacies and Growing 1,200 1161 1 1,150 1,127 1,100 1,075 1,050 1,000 952 1,012 40+ ROFR Without Capital 950 New Stores 895 Joining PharmaChoice Canada (“PCC”) held the right of first 900 Annually refusal on all member
Slide 6: Why Pharmacy?
A SECTOR BUILT FOR STABILITY & GROWTH Why Pharmacy? Recession-Resilient Sector: Essential healthcare spend drives stable cash flows; government and third-party funded Canada’s Aging Population: Prescription demand accelerates after ages 45+ and 65+ Expanded Scope of Practice: Ongoing regulatory chan
Slide 7: A Sector Built for Stability & Growth
A SECTOR BUILT FOR STABILITY & GROWTH Percent of Canadians Aged 65+ 1 19.8% 18.9% 18.0% 17.1% 16.4% 15.6% 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Demographics and accelerating Prescription Drug Use Among Adults (2016-2019) 2 prescription demand create tailwinds for the industry 52% 60
Slide 8: Buy
PharmaCorp 6’
Slide 9: Unique Pipeline Access
OUR SUSTAINABLE COMPETITIVE ADVANTAGE Unique Pipeline Access Exclusive ROFR on Growing Pipeline: 40–50 PCC Retail Collaboration 1,150+ Stores +40 New Stores/ Stores Turn Over Agreement With Ann. Added to Annually = Built-In McKesson Canada PCC Banner Deal Flow 9
Slide 10: Pharmacy Ownership Models
PHARMACY OWNERSHIP MODELS Spectrum of Pharmacy Ownership Models Franchised/ Corporate- Corporate- Banner Pure Owned Affiliated Co-ops Independent 1,150+ 2,000+ 2,000+ 900+ 1. Figures shown above represent the number of pharmacies 10
Slide 11: Range of Acquisition Criteria
RANGE OF ACQUISITION CRITERIA ~$2mm+ ~$350K+ ~35,000+ Annual Revenue Adj. EBITDA 1 Annual Script Count Funding Staffing Acquisition paid partially or Managing pharmacist in full with PharmaCorp with store-level Share Consideration ownership interest 1. Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis) 11
Slide 12: PharmaCorp Rx is an optimal partner to sell to
SELLER RATIONALE Flexible Exit Options Portfolio Exit Planning PharmaCorp Rx is Local Continuity via our Co-Ownership Loan an optimal partner to sell to Equity Upside & Tax Deferral Preserving Legacy 12
Slide 13: Integrate
PharmaCorp
Slide 14: Post-Acquisition Value Creation
POST-ACQUISITION VALUE CREATION Front Shop Growth Opportunity: Pharmacists focus on patient outcomes, leaving the front shop under- managed and under-optimized Our Approach: ▪ Re-energize front shop operations by leveraging PCC’s proven 7.5 – 15% programs ▪ Implement effective planograms to drive hi
Slide 15: Post-Acquisition Target Timelines & Results
POST-ACQUISITION TARGET TIMELINES & RESULTS Initial 30-Day Stabilization Six-Month Optimization Phase One-Year Full Integration Stabilize operations, maintain value, Optimize procurement, inventory, patient Full business review and plan in place. Key continued compliance immediately post- services,
Slide 16: Operate
PharmaCorp 6’
Slide 17: Current Footprint and Capitalized for Growth
CURRENT FOOTPRINT AND CAPITALIZED FOR GROWTH ▪ Owns 17 pharmacies with an expanding pipeline of opportunities ▪ Credit Facility Secured with CIBC: Provides acquisition financing capacity and introduces a pharmacist co-ownership loan program, creating direct alignment, stronger retention and PharmaCo
Slide 18: Q2 2026 Highlights
Q2 2026 HIGHLIGHTS Same Store Script Same Store Sales Adjusted EBITDA1 Count Growth Growth Q2’25 3.5% 11.3% $688.0K Q3’25 7.2% 9.4% $840.6K Q4’25 3.8% 6.0% $1.3M Q1’26 7.2% 7.3% $910.9K Q2’26 5.2% 3.8% $1.7M 1. Adjusted EBITDA (Pre-IFRS 16, 4-Wall basis). See appendix for supporting detail Please no
Slide 19: Expanding Business Development Pipeline
EXPANDING BUSINESS DEVELOPMENT PIPELINE 1 LOI date Opportunity Definitive agreement Status February 27, 2026, replaced PharmaChoice Canada-bannered pharmacy, Share purchase agreement dated Completed October 1, 2026; store by LOI dated June 19, 2026 Western Canada (share purchase) August 10, 2026 cou
Slide 20: Experienced Executive Team
EXPERIENCED EXECUTIVE TEAM Senior Management Team Grady Brown ➢ CEO of PCC for 11+ years (current), growing PCC’s membership from 400 to over 1,100 pharmacies CEO, Director nationwide Paul Dale ➢ Former Executive VP of Operations for Rexall Drugs President, COO ➢ Was responsible for the operation of
Slide 21: Experienced Board of Directors
EXPERIENCED BOARD OF DIRECTORS Board of Directors Alan Simpson ➢ Co-founder of PharmaCorp Executive Chairman, Director ➢ Previously co-founded Hospitality Network Canada and StorageVault Canada (TSX: SVI.T) ➢ StorageVault is Canada’s largest self-storage company with over 200 locations Glenn Fradett
Slide 22: Appendix
PharmaCorp Rd) Appendix
Slide 23: Adjusted EBITDA Reconciliation
ADJUSTED EBITDA RECONCILIATION Q2’25 Q3’25 Q4’25 Q1’26 Q2’26 100% Store-Level Net Income Before Tax 1 512,688 633,837 989,434 579,253 1,168,644 + Depreciation & Amortization 188,277 221,969 341,165 351,862 333,243 + Interest on Long Term Debt 5,352 5,231 4,962 18,959 4,255 + Lease Interest 7,893 10,
Slide 24: Capital Structure
CAPITAL STRUCTURE (AS OF JUNE 30, 2026 ) 1 Common Shares % of Undiluted Total Other Shareholders 2 121,330,931 69.7% Institutions 34,317,400 19.7% Board & Executive Team 3 18,433,328 10.6% Total Shares 174,081,659 100.0% 1. Does not include shares from the bought deal financing, which closed July 14
Slide 25: Q2 2026 Balance Sheet Highlights
Q2 2026 BALANCE SHEET HIGHLIGHTS In C$ 000s Assets Liabilities Cash 24,015 Accounts payable and accruals 3,379 Accounts receivable 1,589 Taxes payable - Inventory 3,128 Current portion of credit facility 316 Prepaid expenses and deposits 137 Current portion of lease liabilities 153 Current portion o
Slide 26: For More Information, Please Contact Us
26 For More Information, Investor Relations Adam.peeler@pharmacorprx.ca Please Contact Us Tel: (416) 427.1235